✦ LIBER ✦

Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells

✍ Scribed by Chuandong Ma; Xiuqing Niu; Jianmin Luo; Zhimin Shao; Kunwei Shen

Book ID: 108586819
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 546 KB
Volume: 101
Category: Article
ISSN: 1347-9032
DOI: 10.1111/j.1349-7006.2010.01662.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Targeting endothelin A receptor enhances

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

✍ Jeanett Fischgräbe; Martin Götte; Katharina Michels; Ludwig Kiesel; Pia Wülfing 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human breast cancers. It is known to drive tumor growth and progression and represents a prominent target in breast cancer therapy. The endothelin (ET) system, in particular ET-1 and its receptor ET A R, is of major relev

Genistein sensitizes inhibitory effect o

Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells

✍ Zhiming Mai; George L. Blackburn; Jin-Rong Zhou 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 267 KB

## Abstract Although tamoxifen (TAM) is used for the front‐line treatment and prevention of estrogen receptor‐positive (ER+) breast tumors, nearly 40% of estrogen‐dependent breast tumors do not respond to TAM treatment. Moreover, the positive response is usually of short duration, and most tumors e

Additive effects of a prolactin receptor

Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells

✍ Michele L. Scotti; John F. Langenheim; Seth Tomblyn; Alison E. B. Springs; Wen Y 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 459 KB

Nordihydroguaiaretic acid (NDGA), an inh

Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells

✍ Marianna Zavodovskaya; Michael J. Campbell; Betty A. Maddux; Laura Shiry; Geoffr 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB 👁 2 views

## Abstract We have reported that nordihydroguaiaretic acid (NDGA) inhibits the tyrosine kinase activities of the IGF‐1 receptor (IGF‐1R) and the HER2 receptor in breast cancer cells. Herein, we studied the effects of NDGA on the growth of estrogen receptor (ER) positive MCF‐7 cells engineered to o

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB 👁 1 views

## Abstract The proteasome plays a pivotal role in the turnover of regulatory transduction proteins induced by activated cell membrane growth factor receptors. The epidermal growth factor receptor (EGFR) pathway is crucial in the development and progression of human epithelial cancers. Proteasome i

Synergistic anti-proliferative and pro-a

Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells

✍ Tina Cascone; Maria Pia Morelli; Floriana Morgillo; Woo-Young Kim; Gabriella Rod 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 29 KB 👁 1 views